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Abstract
T cells have an important role during the development of
autoimmune diseases. In adjuvant arthritis, a model for
rheumatoid arthritis, we found that the percentage of CD4+ T
cells expressing the activation marker CD134 (OX40 antigen)
was elevated before disease onset. Moreover, these CD134+ T
cells showed a specific proliferative response to the disease-
associated epitope of mycobacterial heat shock protein 60,
indicating that this subset contains auto-aggressive T cells. We
studied the usefulness of CD134 as a molecular target for
immune intervention in arthritis by using liposomes coated with
a CD134-directed monoclonal antibody as a drug targeting
system. Injection of anti-CD134 liposomes subcutaneously in
the hind paws of pre-arthritic rats resulted in targeting of the
majority of CD4+CD134+ T cells in the popliteal lymph nodes.
Furthermore, we showed that anti-CD134 liposomes bound to
activated T cells were not internalized. However, drug delivery
by these liposomes could be established by loading anti-CD134
liposomes with the dipalmitate-derivatized cytostatic agent 5'-
fluorodeoxyuridine. These liposomes specifically inhibited the
proliferation of activated CD134+ T cells in vitro, and treatment
with anti-CD134 liposomes containing 5'-fluorodeoxyuridine
resulted in the amelioration of adjuvant arthritis. Thus, CD134
can be used as a marker for auto-aggressive CD4+ T cells early
in arthritis, and specific liposomal targeting of drugs to these
cells via CD134 can be employed to downregulate disease
development.
Introduction
In several autoimmune diseases, for example rheumatoid
arthritis, the involvement of CD4+ T cells in disease induction
has been suggested [1]. As a treatment strategy, the manipu-
lation of CD4+ T cells by CD4-directed antibodies has there-
fore been studied extensively [2]. However, because anti-CD4
therapy targets the whole CD4+ population, CD4+ T cells not
related to the disease or involved in disease regulation will also
be affected. Ideally, only the auto-aggressive CD4+ T cells that
are involved in the disease process should be targeted.
Because for many human autoimmune diseases the exact anti-
gens recognized by these cells are not known, a therapy would
be favorable that specifically targets the auto-aggressive
CD4+ T cells and does not depend on the definition of the cru-
cial auto-antigen.
Because auto-reactive CD4+ T cells become activated upon
recognition of their cognate antigen in the periphery, they will
be transiently marked by the expression of T cell activation
markers. In this respect, CD134 (OX40 antigen) is an interest-
ing candidate target molecule, because CD134 is expressed
in vivo exclusively on activated CD4+ T cells (reviewed in [3]).
In experimental autoimmune encephalomyelitis, a disease
model for multiple sclerosis, it has been shown that CD134 is
preferentially expressed on pathogenic CD4+  T cells that
home to the target organ (namely the central nervous system)
[4], and transiently marks the auto-aggressive T cells specific
AA = adjuvant arthritis; APC = antigen-presenting cells; Con A = concanavalin A; DiD = 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-
chlorobenzenesulfonate salt; FITC = fluorescein isothiocyanate; FUdR(-dP) = 5'-fluoro-2'-deoxyuridine (dipalmitate); HSP = heat shock protein; ILN 
= inguinal lymph nodes; mAb = monoclonal antibody; Mt = Mycobacterium tuberculosis; PBS = phosphate-buffered saline; PE = phycoerythrin; 
PerCP = peridinin chlorophyll protein; PLN = popliteal lymph nodes; s.c. = subcutaneously; SI = stimulation index; TCR = T-cell antigen receptor.Arthritis Research & Therapy    Vol 7 No 3    Boot et al.
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for myelin basic protein [5]. Moreover, in this T cell transfer
model, depletion of CD134+ T cells with an anti-CD134 immu-
notoxin results in the amelioration of paralytic symptoms [6].
Interestingly, in patients with rheumatoid arthritis a high per-
centage of CD4+ T cells in synovial fluid express CD134 in
comparison with peripheral blood T cells [6,7], suggesting
that auto-aggressive CD4+ T cells may be transiently marked
by surface expression of CD134 in arthritis too.
Here, we investigated whether CD134 can be used as a target
for specific drug delivery to activated auto-aggressive CD4+ T
cells in arthritis. For this purpose, the rat adjuvant arthritis (AA)
model was studied. In this model, a syndrome resembling
rheumatoid arthritis is actively induced in Lewis rats after
immunization with Mycobacterium tuberculosis (Mt) in adju-
vant [8]. We first analyzed the CD134 expression on CD4+ T
cells during AA, and investigated the presence of auto-aggres-
sive T cells within the CD134+CD4+ T cell subset. We also
studied drug delivery to CD134+ T cells both in vitro and in
vivo using liposomes coated with a CD134-directed mono-
clonal antibody (mAb) as a drug targeting system. To investi-
gate the possibility for therapeutic intervention in arthritis, anti-
CD134 liposomes were loaded with a cytostatic drug and
administered early in actively induced arthritis. We show that
CD134 can be used as a marker for activated auto-aggressive
T cells early in AA, that targeting of these cells in vivo can be
achieved with anti-CD134 liposomes, and that the course of
AA could be affected with drug-containing anti-CD134
liposomes.
Materials and methods
Animals
Male inbred Lewis rats were obtained from the University of
Limburg (Maastricht, The Netherlands) and were used
between 7 and 10 weeks of age. The animals were kept under
conventional conditions and had access to standard pelleted
rat chow and acidified water ad libitum. The Utrecht University
Animal Ethics Committee approved all animal experiments.
Antigens
Heat-killed Mt, strain H37RA, was obtained from Difco Labo-
ratories (Detroit, Michigan, USA). For immunization, Mt was
suspended in incomplete Freund's adjuvant (Difco Laborato-
ries). Peptides Mt HSP60176–190 (EESNTFGLQLELTEG; one-
letter amino acid codes) (HSP60 stands for heat shock pro-
tein 60), Mt HSP60211–225  (AVLEDPYILLVSSKV) and
OVA323–339 (ISQAVHAAHAEINEAGR) (OVA stands for Oval-
bumin) were obtained from Isogen Bioscience (Maarssen, The
Netherlands).
mAbs and second-step reagents
The anti-CD134 (OX40) and anti-CD25 (OX39) hybridomas
were obtained from the ECACC (Salisbury, UK) [9]. The
12CA5 hybridoma producing IgG2b isotype control mAb was
kindly provided by Dr GJ Strous (Department of Cell Biology
and Institute of Biomembranes, University Medical Center,
Utrecht, The Netherlands). mAbs were isolated from hybrid-
oma supernatant by affinity chromatography with GammaBind
Plus Sepharose (Roche Pharmacia, Uppsala, Sweden). For
ease of flow cytometric detection, some purified mAbs were
biotinylated with D-biotinoyl-ε -aminohexanoic acid-N-hydroxy-
succinimide ester (Roche Molecular Biochemicals, Basel,
Switzerland). Fluorescein isothiocyanate (FITC)-conjugated
anti-CD4 (OX35) and anti-CD45RA (OX33), phycoerythrin
(PE)-conjugated goat-anti-mouse immunoglobulin, PE-conju-
gated streptavidin, peridinin chlorophyll protein (PerCP)-con-
jugated anti-T-cell antigen receptor (anti-TCR)-αβ  (R73) and
IgG1 isotype control (A112), and allophycocyanin-conjugated
streptavidin were purchased from BD Pharmingen (San
Diego, California, USA).
Culture of rat CD4+ T cell clone A2b
The isolation, maintenance, and properties of rat CD4+ T cell
clone A2b have been described previously [10]. The arthri-
togenic T cell clone A2b recognizes the 180 to 188 epitope of
Mycobacterium tuberculosis HSP60 [11]. Cells were cultured
in medium (Iscove's modified Dulbecco's medium (Invitrogen,
Merelbeke, Belgium), supplemented with L-glutamine (2 mM),
2-mercaptoethanol (50 µM), penicillin (50 U/ml) and strepto-
mycin (50 µg/ml)) with 2% heat-inactivated normal rat serum.
Induction of AA
Rats were injected intradermally with 100 µl of Mt in incom-
plete Freund's adjuvant at the base of the tail. For studying
cell-surface marker expression, CD4+ subset specificity during
AA and liposome binding in vivo, 10 mg/ml Mt was used. For
AA treatment studies, rats were immunized with 5 mg/ml Mt
(yielding 100% disease incidence, but lower maximum dis-
ease scores in comparison with 10 mg/ml Mt). Rats were
weighed and examined for clinical signs of arthritis in a semi-
blinded set-up. Severity of arthritis was scored by grading
each paw from 0 to 4 based on erythema, swelling and immo-
bility of the joints, resulting in a maximum score of 16 per ani-
mal [12].
Ex vivo analysis of cell-surface marker expression
Before Mt immunization or 7, 10, 14, 21 or 35 days after-
wards, rats were killed and popliteal lymph nodes (PLN),
inguinal lymph nodes (ILN), spleen, and peripheral blood were
isolated. Single-cell suspensions were prepared by mechani-
cally forcing the organs through a 70 µm mesh; erythrocytes
were removed from the splenocyte and blood suspensions by
Ficoll-Isopaque gradient centrifugation. Cells (2 × 105 per
sample) were labeled with anti-CD134 for 30 min on ice, fol-
lowed by incubation with PE-conjugated goat anti-mouse
immunoglobulin and subsequently with anti-CD4-FITC. The
cells were incubated and washed (between each labeling
step) in blocking buffer (PBS (Cambrex Bio Science, Verviers,
Belgium) containing 4% heat-inactivated rat serum, 1% frac-
tion V BSA (Sigma-Aldrich Chemie, Zwijndrecht, TheAvailable online http://arthritis-research.com/content/7/3/R604
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Netherlands) and 0.1% NaN3). Finally, cells were washed in
PBS, fixed in 2% paraformaldehyde and stored at 4°C in the
dark. Cell-associated fluorescence was analyzed within 10
days on a FACSCalibur using Cell Quest software (Becton
Dickinson, Brussels, Belgium).
Cell sorting and ex vivo proliferation of CD4+ T cell 
subsets
At 7 and 10 days after Mt immunization, PLN, ILN, and spleens
of 10 to 15 rats were isolated and each organ type was
pooled. Single-cell suspensions were prepared as described
above. Cells were washed and incubated in PBS containing
4% heat-inactivated rat serum, and stained with anti-CD134-
biotin/streptavidin-allophycocyanin and anti-CD4-FITC. CD4+,
CD4+CD134- and CD4+CD134+ cells were sorted with a
FACS Vantage and Cell Quest software (Becton Dickinson),
resulting in fractions that were 87 to 97% pure.
Sorted cells were washed and incubated for 72 hours in
medium with 2% heat-inactivated normal rat serum in flat-bot-
tomed 96-well plates (Corning-Costar, Schiphol, The Nether-
lands) at 5 × 104 cells per well in the presence of 30 Gy-
irradiated thymocytes as antigen-presenting cells (APC) (106
cells per well) and concanavalin A (Con A; 2.5 µg/ml) or anti-
gen (20 µg/ml Mt HSP60176–190, 20 µg/ml Mt HSP60211–225).
Finally, cells were pulsed for 18 to 20 hours with [3H]thymi-
dine, 0.4 µCi per well (specific radioactivity 1 Ci/mmol; Amer-
sham Biosciences, Roosendaal, The Netherlands), after which
[3H]thymidine incorporation was measured. Results are pre-
sented as the mean stimulation index (SI, defined as [3H]thy-
midine incorporation in the presence of antigen or Con A
divided by [3H]thymidine incorporation in the absence of anti-
gen or Con A) of triplicate wells. For logistic reasons, ILN sin-
gle-cell suspensions were kept overnight on ice and were
washed, stained and sorted on the following day.
Preparation of (mAb-coupled) PEG-liposomes
Liposomes were composed of egg phosphatidylcholine, cho-
lesterol, poly(ethyleneglycol)2000-distearoylphosphatidyleth-
anolamine (PEG2000-DSPE) and maleimide-PEG2000-DSPE in
a molar ratio of 2:1:0.075:0.075. Egg phosphatidylcholine
was kindly provided by Lipoid (Ludwigshafen, Germany),
PEG2000-DSPE was purchased from Avanti Polar Lipids (Bir-
mingham, Alabama, USA), cholesterol from Sigma-Aldrich
Chemie, and Maleimide-PEG2000-DSPE from Shearwater Pol-
ymers (Huntsville, Alabama, USA). Liposomes used for inves-
tigating liposome binding in vivo contained 0.1 mol% 1,1'-
dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlo-
robenzenesulfonate salt (DiD; Molecular Probes Europe, Lei-
den, The Netherlands). Liposomes used for investigating in
vitro  binding and internalization contained 0.1 mol% Texas
red-phosphatidylethanolamine (Molecular Probes Europe).
Liposomes used for studying drug delivery in vitro and for the
treatment of AA contained 2 mol% 5'-fluoro-2'-deoxyuridine
dipalmitate (FUdR-dP; that is, 0.06 mol FudR-dP per 3 mol
main lipid constituents) (synthesized as described previously
[13]).
Lipids (and FUdR-dP or DiD) were dissolved in chloroform/
methanol (9:1) and mixed. A lipid film was prepared through
rotary evaporation under vacuum and dried under nitrogen.
The lipids were hydrated with HN buffer (4-(2-hydroxyethyl)-1-
piperazine ethanesulphonic acid (HEPES) and 135 mM NaCl)
at pH 6.7. The resulting vesicles were sized by repeated extru-
sion through 100 nm polycarbonate filters. Particle size and
size distribution were determined by dynamic laser light scat-
tering with an Autosizer 4700 Spectrometer (Malvern Instru-
ments, Malvern, Worcestershire, UK). Liposome preparations
had a mean particle diameter ranging from 100 to 200 nm
(polydispersity between 0.1 and 0.2). Typically, the mean lipo-
somal diameter varied by less than 20% within any given
experiment. The anti-CD134 or IgG2b isotype control mAbs
were coupled to liposomes by a thiol-maleimide method
described previously [13]. In brief, free thiol groups were intro-
duced in the mAbs using the heterobifunctional reagent N-
succinimidyl-S-acetylthioacetate (SATA; Sigma-Aldrich
Chemie). Free SATA was separated from the derivatized
mAbs by gel permeation chromatography, resulting in ATA-
derivatized mAbs dissolved in HN buffer at pH 7.4. mAbs with
reactive thiol groups, induced by deacetylating the ATA-pro-
tein, were incubated with liposomes at 4°C overnight at a ratio
of 0.05 to 0.1 mg of mAbs per µmol lipid. N-ethylmaleimide (8
mM in HN buffer, pH 7.4) was added to cap unreacted thiol
groups. Unconjugated mAbs were removed by gel-permeation
chromatography or by centrifugation at 100,000 g. The lipo-
somal protein content was determined as described previ-
ously [14]. Liposomes contained 25 to 125 µg of mAbs per
µmol of lipid. Typically, the mAb content of the different lipo-
some preparations within any given experiment varied by less
than 20%.
Liposome binding to CD4+ T cells in vivo
On day 7 after Mt immunization, rats received saline or 5 µmol
(lipid) DiD-labeled liposomes subcutaneously (s.c.) in each
hind paw. After 30 min the rats were killed, and the PLN, ILN,
and spleens were isolated. Single-cell suspensions were pre-
pared as described above. Subsequently, cells were stained
with anti-CD4-FITC, anti-CD134-biotin/streptavidin-PE and
anti-TCR-αβ -PerCP, or with anti-CD45RA-FITC, anti-CD134-
biotin/streptavidin-PE and anti-TCR-αβ -PerCP. Cell-associ-
ated fluorescence was measured by flow cytometry.
Liposomal drug delivery to T cells in vitro
A2b T cells were activated in vitro to induce CD134 expres-
sion by stimulation overnight with 2.5 µg/ml Con A (Sigma-
Aldrich Chemie) in the presence of 30 Gy-irradiated Lewis thy-
mocytes as APC (ratio of T cells to APC = 1:25). Alternatively,
a spleen cell suspension (at 2 × 105 cells/ml) was stimulated
for 3 days with 2.5 µg/ml Con A to induce CD134 expression
on splenic T cells. Next, viable cells were collected from theArthritis Research & Therapy    Vol 7 No 3    Boot et al.
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culture by Ficoll-Isopaque gradient centrifugation and trans-
ferred to round-bottomed 96-well plates at 105  cells per
sample.
For studying anti-CD134 liposome binding to T cells in vitro by
flow cytometry, A2b cells were incubated with 5 nmol (lipid) of
anti-CD134 liposomes or IgG2b isotype control liposomes, or
anti-CD134 mAb or IgG2b isotype control mAb for 30 min on
ice. Cells were then washed and incubated on ice with FITC-
conjugated goat anti-mouse immunoglobulin to label the cell-
bound mAbs or liposomes. Finally, cell-associated fluores-
cence was measured. For analysis of the interaction of CD4+
T cells and liposomes by confocal microscopy, activated A2b
cells were incubated with 50 nmol of the different liposomal
formulations in medium for 30 min on ice, washed and cultured
in medium with 2% heat-inactivated normal rat serum at 37°C
in 5% CO2. Activated spleen cells were incubated with 100
nmol of liposomes. At the indicated time points, cell-associ-
ated fluorescence was assessed.
For assessment of in vitro drug delivery by anti-CD134 lipo-
somes, activated A2b cells were incubated at 37°C in 5%
CO2 without or with 1 nmol (lipid) of the different liposomal for-
mulations per well or with an equal concentration (100 nM) of
free FUdR (Sigma-Aldrich Chemie) in 200 µl of medium with-
out serum. After 30 min, cells were washed three times in
medium and cultured for 48 hours in 200 µl of conditioned
medium (medium supplemented with 10% heat-inactivated
fetal calf serum (Bodinco, Alkmaar, The Netherlands), 10%
culture supernatant of the EL-4 lymphoma (containing murine
IL-2) and 1% non-essential amino acids (Invitrogen)). Finally,
cells were pulsed for 18 to 20 hours with [3H]thymidine as
described above, after which [3H]thymidine incorporation was
measured. Results are expressed as the mean percentage of
inhibition of proliferation of duplicate cultures relative to the
incubation without liposomes (defined as 0%).
Treatment of AA with liposomes and ex vivo proliferation 
assay of LN cells after liposomal treatment
AA was induced in Lewis rats as described above. Rats
received 5 µmol of the different liposome formulations s.c. in
each hind paw or HN buffer (see below) as a control on days
3 and 7 or on days 3, 7, and 10 after Mt immunization. Rats
were followed for arthritis development as described above.
Proliferation of lymphocytes from liposome-treated animals
was measured in quadruple cultures of 2 × 105 cells per well
without additional APC. Cells were cultured in 96-well flat-bot-
tomed plates in 200 µl of medium containing 2% heat-inacti-
vated normal rat serum in the absence or presence of antigen
(20 µg/ml Mt HSP60176–190 or 20 µg/ml OVA232–339) or Con
A (2.5 µg/ml). After 72 hours, cells were pulsed for 18 to 20
hours with [3H]thymidine as described above, after which
[3H]thymidine incorporation was measured.
Statistical evaluation
The statistical significance of differences was evaluated with
GraphPad Prism 3.02 (GraphPad Software, San Diego, Cali-
fornia, USA). For statistical analysis of CD134 expression in
vivo and liposomal drug delivery in vitro, a one-way analysis of
variance with Dunnett's post-hoc test was used. For analysis
of differences in the development of AA, a Mann-Whitney test
was used for arthritis scores and an unpaired Student's t-test
for body weight.
Results
Expression of CD134 on CD4+ T cells during AA
To study the expression of CD134 and CD4 during AA, Lewis
rats were immunized with Mt in adjuvant. The first signs of
inflammation of the paw joints were observed between days
10 and 14, and the disease reached maximum severity at days
20 to 22. After this, inflammation of paw joints gradually
decreased and resolved macroscopically at days 35 to 40. At
several time points during AA development, the PLN (which
drain the foot and ankle joints), the ILN (which drain the Mt
immunization site), the spleen, and blood were isolated and
examined by flow cytometry.
Seven days after Mt immunization, before the clinical onset of
AA, the percentage of CD134+ T cells was increased both in
the PLN and ILN in comparison with naive animals (day 0; Fig.
1a,b). In the ILN this percentage remained elevated through-
out the active disease phase between days 10 and 30 (Fig.
1b). In the PLN a decrease in the percentage of CD134+ T
cells on days 10 and 14 was observed. On day 21 the per-
centage of CD134+CD4+ cells was found to increase again
(Fig. 1a). The total cell number in the PLN at day 7 (8.5 × 106
± 1.6 × 106, mean ± SEM) and day 10 (8.3 × 106 ± 2.7 × 106)
was comparable, as well as the percentage of CD4+ cells (per-
centage of live lymphocytes; Fig. 1d). This indicated that the
absolute number of CD134+CD4+ T cells decreased during
the interval from day 7 to day 10. In the spleen, the main
increase in the percentage of CD134-expressing T cells was
observed at about day 14 (Fig. 1c). In peripheral blood, no
changes were detected in the percentage of CD134+ cells
during the onset of AA (data not shown). We did not observe
a significant increase in the percentage of CD4+ cells during
AA in any of the organs tested (Fig. 1d–f). The data shown in
Fig. 1 represent a compilation of four separate experiments, in
which all rats were immunized on one day and flow cytometric
analysis was performed on separate days. Another experiment
in which rats were immunized on separate days (n = 4 rats per
time point), and flow cytometric analysis was performed on
one day, yielded similar results (data not shown).
Specific responsiveness of CD134+ T cells to the disease-
associated epitope of Mt HSP60
Previously, it has been shown that a CD4+ T cell clone (clone
A2b [15]), derived from a Lewis rat after Mt immunization and
capable of transferring arthritis to naive rats, recognized a TAvailable online http://arthritis-research.com/content/7/3/R604
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cell epitope present in the 176–190 region of Mt HSP60 (Mt
HSP60176–190) [11]. To investigate whether CD134+ T cells
early in AA were potentially arthritogenic, we tested
CD134+CD4+ T cells isolated at days 7 and 10 after Mt immu-
nization – that is, just before the onset of clinical disease – for
their proliferative response to peptide Mt HSP60176–190. The
results for day 10 are presented in Fig. 2. PLN-derived CD4+
cells showed a low proliferative response to the disease-asso-
ciated peptide (SI ≈  3; Fig. 2). When the CD4+ population was
divided into CD134+ and CD134- fractions, the Mt HSP60176–
190 response of the CD4+ cells was entirely attributable to the
CD134+ cells, as these cells showed a high proliferative activ-
ity to Mt HSP60176–190, whereas this response was absent in
the CD134- population (SI < 2). Similar results were found for
the CD4+ subsets isolated from ILN and spleen (Fig. 2). The
isolated CD134+CD4+  cells also showed a response to
another mycobacterial HSP60 epitope, peptide 211–225,
which has been reported not to be related to AA [16]. How-
ever, this response was much lower than the Mt HSP60176–190
response (Fig. 2). Data obtained at day 7 (data not shown) and
day 10 were similar. Thus, the CD134+ T cell population found
early in AA was enriched for activated auto-aggressive CD4+
T cells, as shown by the specific response to the disease-
associated epitope Mt HSP60176–190.
Specific targeting to CD134+ T cells in draining lymph 
nodes with anti-CD134 liposomes
For delivery of modulating compounds to the potentially arthri-
togenic CD134+ T cells, we selected a mAb-targeted lipo-
somal system. To investigate whether the CD134+ CD4+ T
cells in the draining LN could be targeted in vivo, fluorescent
anti-CD134 liposomes were injected s.c. in the hind paws of
rats on day 7 after Mt immunization. After 30 min, rats were
killed, and the T cells in the joint-draining PLN, the immuniza-
tion site-draining ILN and spleen were studied for CD134
expression and for the presence of cell-bound liposomes by
Figure 1
CD134 is differentially expressed on CD4+ cells in secondary lymphoid organs during adjuvant arthritis CD134 is differentially expressed on CD4+ cells in secondary lymphoid organs during adjuvant arthritis. Popliteal lymph nodes (a,d), inguinal lymph 
nodes (b,e), and spleens (c,f) were isolated from Lewis rats before or during adjuvant arthritis (AA) development. Cell suspensions were stained for 
CD4 and CD134, and cell-associated fluorescence was analyzed by flow cytometry. Results for CD134 (black bars) are depicted as percentages of 
CD134+ cells of the CD4+ cell population and are expressed as means ± SEM (corrected for isotype control fluorescence). Results for CD4 (white 
bars) are shown as percentages of CD4+ cells of the live lymphocytes population and are expressed as means ± SEM (live lymphocytes gated 
based on forward scatter (FSC) and side scatter (SSC) profiles). The data shown are derived from four independent experiments and represent n = 
5 to 7 rats per group for t = 0, n = 2 rats per group for t = 7, n = 3 to 7 rats per group for t = 10, n = 5 to 8 rats per group for t = 14, n = 5 to 9 rats 
per group for t = 21, and n = 4 to 6 rats per group for t = 35. *P < 0.05 compared with t = 0, **P < 0.01 compared with t = 0.Arthritis Research & Therapy    Vol 7 No 3    Boot et al.
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flow cytometry. In the PLN, 10.7% of the cells were found to
be both CD4+ and CD134+, whereas 7.5% of the cells had
bound anti-CD134 liposomes and were CD4+ (Fig. 3a). Com-
petitive counterstaining of liposome+CD4+  cells with anti-
CD134 mAbs showed that virtually all these cells were indeed
CD134+  (Fig. 3b). This implies that the vast majority of
CD134+ T cells in the PLN was targeted. In addition, also
CD4- cells were targeted in the PLN (Fig. 3a). In this case,
however, binding of both anti-CD134- and isotype control lipo-
somes was comparable and these cells were determined to be
CD45RA+ B cells (Fig. 3c). Because B cells do not express
CD134, the anti-CD134 binding could not be due to CD134
binding. The similar staining pattern of isotype control lipo-
somes and anti-CD134 liposomes on B cells suggested that
this binding was due to Fc-mediated binding (because whole
mAb was used to coat liposomes). In the ILN or the spleen vir-
tually no CD134+ CD4+ T cells were targeted by anti-CD134
liposomes administered s.c. in the paw (Fig. 3a).
Drug delivery to CD134+ T cells in vitro using anti-CD134 
liposomes containing the dipalmitate-anchored 
cytostatic agent FUdR
The fate of anti-CD134 liposomes after binding to activated
CD4+ T cells was studied in vitro by incubation of activated T
cells of clone A2b with anti-CD134 liposomes. Activated
CD134+ A2b T cells were shown to specifically bind anti-
CD134 liposomes (Fig. 4a). Interestingly, although resting
A2b cells seemed CD134- after conventional mAb staining,
anti-CD134 liposomes did bind to these cells to a small extent.
Using confocal microscopy, anti-CD134 liposomes were
shown to bind specifically to activated CD4+ T cells in a dif-
fuse pattern; that is, spread out over the plasma membrane
(Fig. 4b). When cells that had bound liposomes were incu-
bated at 37°C, the staining pattern of anti-CD134 liposomes
changed from diffuse to a more focal pattern after 2 hours of
culture at 37°C (Fig. 4b, 2 hours). However, no internalization
of anti-CD134 liposomes was observed at any of the time
points evaluated. This was also observed with Con A-activated
splenic T cells (data not shown). As a positive control for lipo-
some internalization, liposomes targeting CD25, the α -subunit
of the IL-2 receptor, which is also expressed on activated
CD4+ T cells, were used (Fig. 4b, 4 hours). Furthermore, acti-
vated CD4+ T cells were able to internalize anti-CD134 mAbs
(and anti-CD25 mAbs) within 2 hours of binding (data not
shown). This indicated that although the CD134 receptor itself
was internalized, cell-bound anti-CD134 liposomes were not
internalized by the targeted T cells.
Our finding that anti-CD134 liposomes were not internalized
by the target T cells had major implications for the strategy of
drug delivery. We decided to use the mechanism of lipid-cou-
Figure 2
CD134+ T cells recognize the disease-associated mycobacterial epitope early in adjuvant arthritis CD134+ T cells recognize the disease-associated mycobacterial epitope early in adjuvant arthritis. Popliteal lymph nodes, inguinal lymph nodes, and 
spleens were isolated from n = 13 rats at day 10 after immunization with Mycobacterium tuberculosis (Mt). The organs were pooled by organ type, 
and single-cell suspensions were stained for CD4 and CD134. The cells were sorted into CD4+ (white bars), CD4+CD134- (hatched bars), and 
CD4+CD134+ (black bars) fractions. Proliferative responses to 20 µg/ml Mt HSP60176–190 (in which HSP60 stands for heat shock protein 60) were 
tested in a [3H]thymidine incorporation assay. As a control, the proliferation in response to 20 µg/ml Mt HSP60211–225 (not related to disease) was 
tested. Results are expressed as the mean SI of triplicate wells. The cut-off value for proliferation was set at SI = 2 (indicated by the horizontal line). 
Shown is one representative experiment of three.Available online http://arthritis-research.com/content/7/3/R604
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Figure 3
CD134+ T cells in joint-draining lymph nodes are targeted by subcutaneous injection of anti-CD134 liposomes CD134+ T cells in joint-draining lymph nodes are targeted by subcutaneous injection of anti-CD134 liposomes. On day 7 after immunization with 
Mycobacterium tuberculosis (Mt), rats were injected subcutaneously with fluorescent isotype control liposomes or anti-CD134 liposomes. Rats 
were killed 30 min later, and popliteal lymph nodes (PLN), inguinal lymph nodes, and spleens were isolated. (a) Cells were stained for CD4 and T-
cell antigen receptor (TCR)-αβ  and cell-associated fluorescence was analyzed by flow cytometry. Dot plots show cell-associated fluorescence due 
to in vitro monoclonal antibody (mAb) staining (left panels) or in vivo liposome binding (right panels). Cells were gated for live TCR-αβ + CD4+ cells. 
The numbers in the dot plots indicate the percentage of cells above the cut-off line, which was set by using non-stained cells from sham-injected ani-
mals. Three rats were analyzed per group; representative stainings of one rat per group were selected and are shown here. (b) PLN cells of anti-
CD134 liposome-injected rats were stained with anti-CD4 and anti-CD134 or its isotype control. Cells were gated for live CD4+liposome+ cells. His-
tograms show cell-associated fluorescence due to the binding of anti-CD134 (filled) or isotype control mAb (open). Representative stainings of one 
rat of three are shown. (c) PLN cells were stained with anti-TCR-αβ  and anti-CD45RA (rat B cells). Cells were gated for live, TCR-αβ -, and lipo-
some+ cells. Histograms show cell-associated fluorescence due to ex vivo CD45RA (filled histogram) or isotype control mAb staining (thin line) on 
anti-CD134 liposome+ cells, or CD45RA (thick line) mAb staining on isotype control liposome+ cells. Representative stainings of one rat of three are 
shown.Arthritis Research & Therapy    Vol 7 No 3    Boot et al.
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pled drug transfer between membranes to achieve intracellular
drug delivery. The lipid-derivatized cytostatic agent FUdR-dP
was used as a model drug [13]. Activated, CD134+ rat T cells
of clone A2b were found to be very sensitive to free FUdR
(90% growth inhibition with 100 nM FUdR) when FUdR was
continuously present during culture for 48 hours. However,
when the cells were incubated for only 30 min with free FUdR
and then washed to remove extracellular FUdR, no significant
growth inhibition was detected during subsequent culture
(Table 1). When the equivalent amount of FUdR was present
in 1 nmol anti-CD134 liposomes (anti-CD134-FUdR-dP lipo-
somes), which were incubated for 30 min with the cells, the
proliferation of activated A2b cells was inhibited by more than
30% (Table 1). Incubation of activated T cells with anti-CD134
liposomes without FUdR-dP or with non-targeted FUdR-dP
liposomes did not significantly affect the proliferation of the
cells (P > 0.05; Table 1).
Modulation of AA by treatment with drug-containing 
anti-CD134 liposomes
Next, we investigated whether local targeting to CD134+ T
cells in the joint-draining PLN would affect the course of
actively induced arthritis in the AA model. Rats were injected
with the different liposomal formulations on days 3 and 7 after
Mt immunization and were followed for arthritis development.
Injection of anti-CD134-FUdR-dP liposomes resulted in less
severe disease development than in rats injected with anti-
CD134 liposomes without FUdR-dP (Fig. 5a). This effect was
increased by the administration of anti-CD134-FudR-dP lipo-
somes on three occasions (Fig. 5b). The improved well-being
of the anti-CD134-FUdR-dP liposome-treated rats was also
reflected in a faster recovery of weight (Fig. 5a). The isotype
control FUdR-dP liposomes also seemed to affect the pro-
gression of AA, although anti-CD134-FUdR-dP liposomes
were more effective. No difference in AA scores was found
between rats treated with empty anti-CD134 liposomes and
rats treated with empty, bare liposomes (data not shown).
The modulation of the course of AA after treatment with anti-
CD134-FUdR-dP liposomes was correlated with a decreased
proliferative response to Mt HSP60176–190 of joint-draining
PLN cells isolated at day 42 (Fig. 5c). This is indicative of suc-
cessful targeting and deletion of Mt HSP60176–190-reactive,
CD134+ T cells in vivo.
Discussion
In the present study we investigated whether CD134 can be
used as a (transient) marker for targeting auto-aggressive
CD4+ T cells in actively induced experimental arthritis. Before
the onset of clinical arthritis, an elevated percentage of
CD134+ CD4+ T cells was found in the PLN, which drain the
foot and ankle joints, and in the ILN, which drain the Mt immu-
nization site. In the ILN, this percentage remained elevated
throughout the active disease phase, indicating a continuous
activation of T cells, probably because of the presence of an
Mt depot at the base of the tail. However, in the PLN the per-
centage and absolute number of CD134+  T cells were
decreased at days 10 and 14 after immunization in compari-
son with the initial elevation on day 7. In this arthritis model, the
first signs of clinical disease become manifest between days
10 and 14, and at about this time T cells start to infiltrate the
joints [17]. The present data therefore suggest that early in
AA, CD134+ T cells, after activation in the PLN, can migrate to
Figure 4
Anti-CD134-mediated targeting does not lead to liposome internaliza- tion by activated CD4+ T cells in vitro Anti-CD134-mediated targeting does not lead to liposome internaliza-
tion by activated CD4+ T cells in vitro. A2b T cells were cultured with 
antigen-presenting cells and Con A to induce CD134 expression; 
CD25 is expressed constitutively on these cells. (a) Viable T cells were 
incubated with isotype control liposomes (filled histogram) or with anti-
CD134 liposomes (black line). As a control, the binding of anti-CD134 
liposomes or anti-CD134 monoclonal antibodies to resting T cells was 
assessed (gray lines). Cell-associated fluorescence was analyzed by 
flow cytometry, with live cells gated on the basis of forward scatter 
(FSC) and side scatter (SSC) profiles. One representative experiment 
of three is shown. (b) Viable T cells were incubated for 30 min with anti-
CD134 liposomes on ice. After the removal of non-bound liposomes by 
washing, cells were cultured subsequently at 37°C. Samples were 
taken at the indicated time points and analyzed for the cellular localiza-
tion of the liposomal fluorescence with the use of confocal microscopy. 
A representative cell from each time point is shown. As a positive con-
trol for cellular internalization of liposomes, cells incubated with anti-
CD25 liposomes are shown. One of two experiments, yielding similar 
results, is shown.Available online http://arthritis-research.com/content/7/3/R604
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the joints, where they subsequently become involved in joint
inflammation. The second increase in the percentage of
CD134-expressing T cells in the PLN on days 21 and 35 could
reflect the recirculation or generation of activated auto-aggres-
sive T cells, or the emergence of an activated regulatory
population.
The presence of arthritogenic cells in the CD134+ subset of
CD4+ T cells isolated from pre-arthritic rats was deduced from
the high proliferative response to the Mt HSP60176–190 pep-
tide, which was previously linked to the induction of AA [11].
However, the CD134+ T cell subset also includes activated
(auto-aggressive) T cells with a different specificity. The low
but evident response of isolated CD4+CD134+ cells to Mt
HSP60211–225, which was reported not to be related to AA
[16], indeed indicated that a part of the CD134+ T cells was
not activated in relation to clinical disease but responded to
other epitopes present in the immunization mix. This underlines
the fact that, although CD134 may be used to select for acti-
vated pathogenic CD4+ T cells in an autoimmune setting, this
molecule is primarily a marker for activated CD4+ T cells in
general [18-20]. Nevertheless, by using CD134 as marker for
targeting, we expected to affect all recently activated auto-
aggressive CD4+ T cells present at the time of targeting,
including arthritogenic T cells with a different specificity from
that of Mt HSP60176–190. The preferential expression of
CD134 on synovial fluid CD4+ T cells from patients with rheu-
matoid arthritis, as has been demonstrated by others [6,7,21],
indicates that also in humans auto-reactive T cells might be
(transiently) marked by CD134. Because CD134 ligand
expression has been demonstrated both on vascular endothe-
lial cells [22,23] and in synovial tissue of rheumatoid arthritis
patients [21], the recruitment and in situ restimulation of acti-
vated T cells through CD134 possibly contributes to the
inflammatory process in arthritis. Indeed, in a mouse collagen-
induced arthritis model, treatment with a mAb blocking anti-
CD134 ligand did inhibit disease development [21].
To explore the possibility for modulating auto-aggressive T
cells in arthritis, we examined the potential of drug targeting
directly to CD134+ T cells in AA by using liposomes as drug
carriers. To study the ability of anti-CD134 liposomes to reach
the potentially auto-reactive CD134+ T cells in vivo, the active
disease model was employed, because this would allow tar-
geting of the target T cells during priming in situ; that is, in the
secondary lymphoid organs. When anti-CD134 liposomes
were injected s.c. in the hind paws, the majority of the
CD4+CD134+ T cells in the joint-draining PLN could indeed
be targeted. The non-T cells in the PLN that were found to bind
both anti-CD134 liposomes and isotype control liposomes
were determined as being B cells that most probably bound
the liposomes in a Fc-mediated fashion.
Activated CD134+ T cells targeted by anti-CD134 liposomes
in vitro did not internalize the cell-bound liposomes. This lack
of internalization determined the strategy of drug delivery. We
here employed the mechanism of lipid-coupled drug transfer
between membranes to achieve intracellular drug delivery.
When anti-CD134 liposomes carried the lipid-coupled cyto-
static agent FUdR as a model drug, a 30% inhibition of prolif-
eration of activated CD134+ T cells was observed in vitro. This
inhibitory effect on the proliferation of CD134+ T cells in vitro
was correlated with a moderate suppression of AA in rats
treated with anti-CD134-FUdR-dP liposomes. The effect of
these liposomes on AA development was supported by a
downregulation of the disease-associated Mt HSP60176–190
response in the PLN of anti-CD134-FUdR-dP liposome-
treated animals.
The effect of isotype control-FUdR-dP on clinical disease
might be due to their association with B cells in vivo, probably
through binding to Fc receptors [24]. Although B cells have
not been described as having a crucial role in the development
of AA [25], contrary to collagen-induced arthritis in mice, for
example [26], these cells can function as APC and as such
Table 1
Anti-CD134 5'-fluoro-2'-deoxyuridine dipalmitate liposomes inhibit the proliferation of CD134+ T cells in vitro
Drug Drug carrier Targeting moiety Inhibition of proliferation (%)
None None None 0.0 ± 8.2
FUdR None Anti-CD134 8.9 ± 8.7
FUdR-dP Liposomes None 6.3 ± 0.7
None Liposomes Anti-CD134 0.6 ± 1.1
FUdR-dP Liposomes Anti-CD134 31.0 ± 2.3*
Con A-activated CD134+ T cells of clone A2b were incubated for 30 min without ('none' under the heading 'drug') or with either free 5'-fluoro-2'-
deoxyuridine (FUdR), 5'-fluoro-2'-deoxyuridine dipalmitate (FUdR-dP) liposomes, anti-CD134 liposomes, or anti-CD134-FUdR-dP liposomes. To 
each well was added 100 nM FUdR or 1 nmol of liposomal lipid (for FUdR-dP liposomes this equals 100 nM FUdR). Subsequently, cells were 
washed and cultured for 48 hours, followed by [3H]thymidine incorporation as a measure of proliferation. Results are expressed as the mean 
percentage of inhibition of proliferation relative to the incubation without liposomes (defined as 0%; mean [3H]thymidine incorporation of 53,330 
c.p.m.). Results in the last column are means ± SEM. One representative experiment of three is shown. *P < 0.001 compared with incubation 
without liposomes.Arthritis Research & Therapy    Vol 7 No 3    Boot et al.
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may affect the response of auto-aggressive T cells in vivo.
Optimizing the therapeutic entity, for example by coupling anti-
CD134 Fab fragments to the liposomal carrier instead of the
entire anti-CD134 antibody, would circumvent B cell
targeting.
It has recently been shown that CD4+CD25+ regulatory T cells
involved in the control of autoimmunity [27] can express
CD134 [28-30]. Although CD134+ regulatory T cells may go
through a proliferative phase in vivo [31,32], in general these
cells display a hypoproliferative phenotype in vitro as well as
in vivo [33]. Because cytostatic agents act primarily on prolif-
erating cells, it is possible that by employing FUdR-dP-con-
taining anti-CD134 liposomes we largely preserved this
regulatory T cell subset.
Conclusion
We show here that CD134 can be used as a marker for
recently activated CD4+ T cells with auto-aggressive potential
in arthritis, and that anti-CD134 liposomes can be used to
Figure 5
Adjuvant arthritis is modulated by treatment with anti-CD134 5'-fluoro-2'-deoxyuridine dipalmitate (FUdR-dP) liposomes Adjuvant arthritis is modulated by treatment with anti-CD134 5'-fluoro-2'-deoxyuridine dipalmitate (FUdR-dP) liposomes. (a) Rats were immunized 
with Mycobacterium tuberculosis (Mt) to induce arthritis. On days 3 and 7, rats received isotype control FUdR-dP liposomes (filled triangles), anti-
CD134-FUdR-dP liposomes (filled circles), or empty anti-CD134 liposomes (open circles) subcutaneously (s.c.) in both hind paws. (b) Alternatively, 
after immunization with Mt, on days 3 and 7 rats received anti-CD134-FUdR-dP liposomes (filled circles) or empty bare liposomes (open diamonds), 
or on days 3, 7, and 10 anti-CD134-FUdR-dP liposomes (filled squares), s.c. in both hind paws. Rats were followed for the development of clinical 
disease and body weight until the disease resolved spontaneously (day 37 to 42). Results are expressed as the arthritis score and the mean body 
weight (percentage of day 0) per group of n = 5 rats and are presented as means ± SEM. Statistical differences are indicated in the plots. (c) On 
day 42, rats shown in (a) were killed; popliteal lymph node cells were isolated and pooled from each treatment group. Cells from isotype control 
FUdR-dP liposome-treated rats (white bars), anti-CD134-FUdR-dP liposome-treated rats (black bars), and empty anti-CD134 liposome-treated rats 
(hatched bars) were tested for their proliferative response to 20 µg/ml Mt HSP60176–190 peptide (in which HSP60 stands for heat shock protein 60) 
in a [3H]thymidine incorporation assay. The proliferation to 20 µg/ml peptide OVA323–339 is shown as a negative control. Results are expressed as 
the mean SI for quadruple wells. The cut-off value for proliferation was set at SI 2 (indicated by line).Available online http://arthritis-research.com/content/7/3/R604
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target drugs directly to these T cells. Thus, anti-CD134 lipo-
somes represent an attractive method for the development of
therapies aiming at the modulation of auto-aggressive T cells
for intervention in autoimmune diseases.
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